Literature DB >> 31705870

Freezing of Biologicals Revisited: Scale, Stability, Excipients, and Degradation Stresses.

Jean-Rene Authelin1, Miguel A Rodrigues2, Serguei Tchessalov3, Satish K Singh4, Timothy McCoy5, Stuart Wang6, Evgenyi Shalaev7.   

Abstract

Although many biotech products are successfully stored in the frozen state, there are cases of degradation of biologicals during freeze storage. These examples are discussed in the Perspective to emphasize the fact that stability of frozen biologicals should not be taken for granted. Frozen-state degradation (predominantly, aggregation) has been linked to crystallization of a cryoprotector in many cases. Other factors, for example, protein unfolding (either due to cold denaturation or interaction of protein molecules with ice crystals), could also contribute to the instability. As a hypothesis, additional freezing-related destabilization pathways are introduced in the paper, that is, air bubbles formed on the ice crystallization front, and local pressure and mechanical stresses due to volume expansion during water-to-ice transformation. Furthermore, stability of frozen biologicals can depend on the sample size, via its impact on the freezing kinetics (i.e., cooling rates and freezing time) and cryoconcentration effects, as well as on the mechanical stresses associated with freezing. We conclude that, although fundamentals of freezing processes are fairly well described in the current literature, there are important gaps to be addressed in both scientific foundations of the freezing-related manufacturing processes and implementation of the available knowledge in practice.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Keywords:  biotechnology; formulation; freeze-drying; physical stability; protein aggregation; protein formulation(s); protein(s)

Mesh:

Substances:

Year:  2019        PMID: 31705870     DOI: 10.1016/j.xphs.2019.10.062

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Lyophilization Serves as an Effective Strategy for Drug Development of the α9α10 Nicotinic Acetylcholine Receptor Antagonist α-Conotoxin GeXIVA[1,2].

Authors:  Zhiguo Li; Xiaolu Han; Xiaoxuan Hong; Xianfu Li; Jing Gao; Hui Zhang; Aiping Zheng
Journal:  Mar Drugs       Date:  2021-02-25       Impact factor: 5.118

2.  The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - part 2: Aggregate formation and oxidation.

Authors:  Oliver Bluemel; Jakob W Buecheler; Astrid Hauptmann; Georg Hoelzl; Karoline Bechtold-Peters; Wolfgang Friess
Journal:  Int J Pharm X       Date:  2021-12-25

3.  The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - Part 1: Higher molecular weight species and subvisible particle formation.

Authors:  Oliver Bluemel; Moritz Anuschek; Jakob W Buecheler; Georg Hoelzl; Karoline Bechtold-Peters; Wolfgang Friess
Journal:  Int J Pharm X       Date:  2021-12-25

4.  The Role of Cyclodextrins against Interface-Induced Denaturation in Pharmaceutical Formulations: A Molecular Dynamics Approach.

Authors:  Marcello Rospiccio; Andrea Arsiccio; Gerhard Winter; Roberto Pisano
Journal:  Mol Pharm       Date:  2021-05-17       Impact factor: 4.939

5.  Stability Studies of the Vaccine Adjuvant U-Omp19.

Authors:  M Laura Darriba; María L Cerutti; Laura Bruno; Juliana Cassataro; Karina A Pasquevich
Journal:  J Pharm Sci       Date:  2020-10-12       Impact factor: 3.534

6.  Biological Activity of Pulcherrimin from the Meschnikowia pulcherrima Clade.

Authors:  Dorota Kregiel; Maria Nowacka; Anna Rygala; Renáta Vadkertiová
Journal:  Molecules       Date:  2022-03-12       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.